Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis

W. Zheng, X.B. Li, Y.Q. Xiang, B.L. Zhong, H.F.K. Chiu, Gabor Ungvari, C.H. Ng, G.K.I. Lok, Y.T. Xiang

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd. Objective To review the efficacy and safety of aripiprazole (ARI) for Tourette's syndrome (TS). Methods This review included randomized controlled trials (RCTs) of children and adolescents (6-18 years) with TS comparing ARI monotherapy with another monotherapies in relation to clinical improvement and adverse events. Results Six RCTs with a total of 528 subjects (ARI treatment group: n = 253; control group: n = 275) met the inclusion criteria. These included two RCTs (n = 255) that compared ARI monotherapy with tiapride (TIA). Tic symptoms control assessed by Yale Global Tic Severity Scale (Standard Mean Difference (SMD) = -0.38 (Confidence Interval (CI) = -1.32 to 0.56); I2 = 90%, P = 0.42) revealed no significant differences between the two groups. Extrapyramidal symptoms were significantly different when ARI (1.5%) was compared with haloperidol (HAL) (43.5%). No significant group differences were found in the rates of nausea/vomiting, dizziness, and dry mouth between ARI and TIA (RR = 0.57 to 1.00 (95%CI = 0.14-4.20); I2 = 0% to 69%, P = 0.35 to 1.00). Conclusion This review found that ARI has similar efficacy to TIA and HAL for TS, while extrapyramidal symptoms were significantly less with ARI than with HAL. ARI can be considered as an alternative treatment option for TS.
    Original languageEnglish
    Pages (from-to)11-18
    JournalHuman Psychopharmacology
    Volume31
    Issue number1
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Tourette Syndrome
    Meta-Analysis
    Tiapride Hydrochloride
    Haloperidol
    Tics
    Randomized Controlled Trials
    Nuclear Family
    Confidence Intervals
    Aripiprazole
    Dizziness
    Nausea
    Vomiting
    Mouth
    Safety
    Control Groups

    Cite this

    Zheng, W., Li, X. B., Xiang, Y. Q., Zhong, B. L., Chiu, H. F. K., Ungvari, G., ... Xiang, Y. T. (2016). Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis. Human Psychopharmacology, 31(1), 11-18. https://doi.org/10.1002/hup.2498
    Zheng, W. ; Li, X.B. ; Xiang, Y.Q. ; Zhong, B.L. ; Chiu, H.F.K. ; Ungvari, Gabor ; Ng, C.H. ; Lok, G.K.I. ; Xiang, Y.T. / Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis. In: Human Psychopharmacology. 2016 ; Vol. 31, No. 1. pp. 11-18.
    @article{77ae4575ceb147f39aa016423b56c9fa,
    title = "Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis",
    abstract = "Copyright {\circledC} 2015 John Wiley & Sons, Ltd. Copyright {\circledC} 2015 John Wiley & Sons, Ltd. Objective To review the efficacy and safety of aripiprazole (ARI) for Tourette's syndrome (TS). Methods This review included randomized controlled trials (RCTs) of children and adolescents (6-18 years) with TS comparing ARI monotherapy with another monotherapies in relation to clinical improvement and adverse events. Results Six RCTs with a total of 528 subjects (ARI treatment group: n = 253; control group: n = 275) met the inclusion criteria. These included two RCTs (n = 255) that compared ARI monotherapy with tiapride (TIA). Tic symptoms control assessed by Yale Global Tic Severity Scale (Standard Mean Difference (SMD) = -0.38 (Confidence Interval (CI) = -1.32 to 0.56); I2 = 90{\%}, P = 0.42) revealed no significant differences between the two groups. Extrapyramidal symptoms were significantly different when ARI (1.5{\%}) was compared with haloperidol (HAL) (43.5{\%}). No significant group differences were found in the rates of nausea/vomiting, dizziness, and dry mouth between ARI and TIA (RR = 0.57 to 1.00 (95{\%}CI = 0.14-4.20); I2 = 0{\%} to 69{\%}, P = 0.35 to 1.00). Conclusion This review found that ARI has similar efficacy to TIA and HAL for TS, while extrapyramidal symptoms were significantly less with ARI than with HAL. ARI can be considered as an alternative treatment option for TS.",
    author = "W. Zheng and X.B. Li and Y.Q. Xiang and B.L. Zhong and H.F.K. Chiu and Gabor Ungvari and C.H. Ng and G.K.I. Lok and Y.T. Xiang",
    year = "2016",
    doi = "10.1002/hup.2498",
    language = "English",
    volume = "31",
    pages = "11--18",
    journal = "Human Psychopharmacology: Clinical and Experimental",
    issn = "0885-6222",
    publisher = "John Wiley & Sons",
    number = "1",

    }

    Zheng, W, Li, XB, Xiang, YQ, Zhong, BL, Chiu, HFK, Ungvari, G, Ng, CH, Lok, GKI & Xiang, YT 2016, 'Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis' Human Psychopharmacology, vol. 31, no. 1, pp. 11-18. https://doi.org/10.1002/hup.2498

    Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis. / Zheng, W.; Li, X.B.; Xiang, Y.Q.; Zhong, B.L.; Chiu, H.F.K.; Ungvari, Gabor; Ng, C.H.; Lok, G.K.I.; Xiang, Y.T.

    In: Human Psychopharmacology, Vol. 31, No. 1, 2016, p. 11-18.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Aripiprazole for Tourette's syndrome: A systematic review and meta-analysis

    AU - Zheng, W.

    AU - Li, X.B.

    AU - Xiang, Y.Q.

    AU - Zhong, B.L.

    AU - Chiu, H.F.K.

    AU - Ungvari, Gabor

    AU - Ng, C.H.

    AU - Lok, G.K.I.

    AU - Xiang, Y.T.

    PY - 2016

    Y1 - 2016

    N2 - Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd. Objective To review the efficacy and safety of aripiprazole (ARI) for Tourette's syndrome (TS). Methods This review included randomized controlled trials (RCTs) of children and adolescents (6-18 years) with TS comparing ARI monotherapy with another monotherapies in relation to clinical improvement and adverse events. Results Six RCTs with a total of 528 subjects (ARI treatment group: n = 253; control group: n = 275) met the inclusion criteria. These included two RCTs (n = 255) that compared ARI monotherapy with tiapride (TIA). Tic symptoms control assessed by Yale Global Tic Severity Scale (Standard Mean Difference (SMD) = -0.38 (Confidence Interval (CI) = -1.32 to 0.56); I2 = 90%, P = 0.42) revealed no significant differences between the two groups. Extrapyramidal symptoms were significantly different when ARI (1.5%) was compared with haloperidol (HAL) (43.5%). No significant group differences were found in the rates of nausea/vomiting, dizziness, and dry mouth between ARI and TIA (RR = 0.57 to 1.00 (95%CI = 0.14-4.20); I2 = 0% to 69%, P = 0.35 to 1.00). Conclusion This review found that ARI has similar efficacy to TIA and HAL for TS, while extrapyramidal symptoms were significantly less with ARI than with HAL. ARI can be considered as an alternative treatment option for TS.

    AB - Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd. Objective To review the efficacy and safety of aripiprazole (ARI) for Tourette's syndrome (TS). Methods This review included randomized controlled trials (RCTs) of children and adolescents (6-18 years) with TS comparing ARI monotherapy with another monotherapies in relation to clinical improvement and adverse events. Results Six RCTs with a total of 528 subjects (ARI treatment group: n = 253; control group: n = 275) met the inclusion criteria. These included two RCTs (n = 255) that compared ARI monotherapy with tiapride (TIA). Tic symptoms control assessed by Yale Global Tic Severity Scale (Standard Mean Difference (SMD) = -0.38 (Confidence Interval (CI) = -1.32 to 0.56); I2 = 90%, P = 0.42) revealed no significant differences between the two groups. Extrapyramidal symptoms were significantly different when ARI (1.5%) was compared with haloperidol (HAL) (43.5%). No significant group differences were found in the rates of nausea/vomiting, dizziness, and dry mouth between ARI and TIA (RR = 0.57 to 1.00 (95%CI = 0.14-4.20); I2 = 0% to 69%, P = 0.35 to 1.00). Conclusion This review found that ARI has similar efficacy to TIA and HAL for TS, while extrapyramidal symptoms were significantly less with ARI than with HAL. ARI can be considered as an alternative treatment option for TS.

    U2 - 10.1002/hup.2498

    DO - 10.1002/hup.2498

    M3 - Article

    VL - 31

    SP - 11

    EP - 18

    JO - Human Psychopharmacology: Clinical and Experimental

    JF - Human Psychopharmacology: Clinical and Experimental

    SN - 0885-6222

    IS - 1

    ER -